Large-vessel vasculitis following the Pfizer-BioNTech COVID-19 vaccine

World Health Organization. Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed 20 Oct 2020

Brack A, Martinez-Taboada V, Stanson A et al (1999) Disease pattern in cranial and large vessel giant cell arteritis. Arthritis Rheum 42:311–317

Hellmich B, Agueda A, Monti S et al (2018) Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020(79):19–30

Bonetto C, Trotta F, Felicetti P et al (2016) Vasculitis as an adverse event following immunization—systematic literature review. Vaccine 34:6641–6651

Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383:2603–2615